KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Equity Income: 2024-2025

Historic Equity Income for Castle Biosciences (CSTL) over the last 1 years, with Sep 2025 value amounting to $3.6 million.

  • Castle Biosciences' Equity Income was N/A to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year change of. This contributed to the annual value of $600,000 for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Equity Income is $3.6 million, which was up 200.00% from $1.2 million recorded in Q2 2025.
  • Castle Biosciences' Equity Income's 5-year high stood at $3.6 million during Q3 2025, with a 5-year trough of -$1.4 million in Q1 2025.
  • In the last 2 years, Castle Biosciences' Equity Income had a median value of $900,000 in 2024 and averaged $993,750.